{"abstract":"The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the proposed rule that appeared in the Federal Register of May 6, 2026, to modify certain terminology in Title 21 of the Code of Federal Regulations (CFR) to comply with Executive Order (E.O.) 14168, \"Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government,\" issued on January 20, 2025. Specifically, this proposed rule, if finalized, will remove the term \"gender\" wherever it appears and either replace it with the term \"sex,\" or delete reference to gender, as applicable, along with other editorial changes to improve readability. The Agency is taking this action to allow interested persons additional time to submit comments.","action":"Proposed rule; reopening of the comment period.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/08/03/2026-15671.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"10","title":21},{"chapter":null,"citation_url":null,"part":"56","title":21},{"chapter":null,"citation_url":null,"part":"106","title":21},{"chapter":null,"citation_url":null,"part":"201","title":21},{"chapter":null,"citation_url":null,"part":"251","title":21},{"chapter":null,"citation_url":null,"part":"310","title":21},{"chapter":null,"citation_url":null,"part":"312","title":21},{"chapter":null,"citation_url":null,"part":"314","title":21},{"chapter":null,"citation_url":null,"part":"329","title":21},{"chapter":null,"citation_url":null,"part":"600","title":21},{"chapter":null,"citation_url":null,"part":"803","title":21},{"chapter":null,"citation_url":null,"part":"862","title":21},{"chapter":null,"citation_url":null,"part":"866","title":21},{"chapter":null,"citation_url":null,"part":"870","title":21},{"chapter":null,"citation_url":null,"part":"882","title":21},{"chapter":null,"citation_url":null,"part":"1114","title":21}],"citation":"91 FR 48785","comment_url":null,"comments_close_on":"2026-10-02","correction_of":null,"corrections":[],"dates":"FDA is reopening the comment period on the proposed rule published on May 6, 2026 (91 FR 24380). Submit either electronic or written comments on the proposed rule by October 2, 2026.","disposition_notes":null,"docket_ids":["Docket No. FDA-2026-N-2886"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":null,"comment_start_date":null,"updated_at":"2026-08-03T09:56:11.660-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2026-N-2886-0002","allow_late_comments":false,"id":"FDA-2026-N-2886-0002","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2026-N-2886","title":"Modification of certain terminology in Title 21"}],"document_number":"2026-15671","effective_on":null,"end_page":48786,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/08/03/2026-15671.xml","html_url":"https://www.federalregister.gov/documents/2026/08/03/2026-15671/modification-of-certain-terminology-in-title-21-reopening-of-the-comment-period","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-15671?publication_date=2026-08-03","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-08-03/2026-15671/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":510,"last_updated":"2026-08-07 10:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15671.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15671.pdf?1785501916","publication_date":"2026-08-03","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/08/03/2026-15671.txt","regulation_id_number_info":{"0910-AJ26":null},"regulation_id_numbers":["0910-AJ26"],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2026-N-2886","supporting_documents_count":0,"docket_id":"FDA-2026-N-2886","document_id":"FDA-2026-N-2886-0002","regulation_id_number":null,"title":"Modification of certain terminology in Title 21","checked_regulationsdotgov_at":"2026-08-04T16:55:04Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":48785,"subtype":null,"title":"Modification of Certain Terminology in Title 21; Reopening of the Comment Period","toc_doc":"Modification of Certain Terminology","toc_subject":null,"topics":[],"type":"Proposed Rule","volume":91}